NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors
-
Published:2024-08
Issue:
Volume:597
Page:217042
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Vidana Gamage Hashni EpaORCID, Shahoei Sayyed HamedORCID, Wang Yu, Jacquin EliseORCID, Weisser Erin, Bautista Rafael O., Henn Madeline A., Schane Claire P.ORCID, Nelczyk Adam T.ORCID, Ma LiqianORCID, Das Gupta AnasuyaORCID, Bendre Shruti V.ORCID, Nguyen Tiffany, Tiwari Srishti, Tjoanda Evelyn, Krawczynska NataliaORCID, He SisiORCID, Albright Samuel T., Farmer Rachel, Smith Amanda J.ORCID, Fink Emma C., Chen Hong, Sverdlov Maria, Gann Peter H., Boidot RomainORCID, Vegran Frederique, Fanning Sean W.ORCID, Hergenrother Paul J., Apetoh LionelORCID, Nelson Erik R.ORCID
Reference70 articles.
1. T.A.C. Society, Survival Rates for Breast Cancer. 2. Event-free survival with pembrolizumab in early triple-negative breast cancer;Schmid;N. Engl. J. Med.,2022 3. Checkpoint inhibitors in breast cancer - Current status;Polk;Cancer Treat Rev.,2018 4. Immune checkpoint blockade for breast cancer;Swoboda;Cancer Treat Res.,2018 5. Immunotherapy for breast cancer: what are We missing?;Vonderheide;Clin. Cancer Res. : an official journal of the American Association for Cancer Research,2017
|
|